Quantcast

Latest Lymphoma Stories

2014-10-29 08:34:22

This Year Marks the 20th Anniversary of LLS's Prestigious Translational Research Program WHITE PLAINS, N.Y., Oct. 29, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) is awarding $15.6 million in academic grants to 26 scientists who have proposed innovative laboratory research that shows promise in leading to new treatments for blood cancer patients. The funds are being awarded through LLS's Translational Research Program (TRP), which aims to accelerate...

2014-10-29 08:32:28

DALLAS, October 29, 2014 /PRNewswire/ -- ReportsnReports.com adds Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options research report to its store. This research provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany,...

2014-10-28 12:31:13

The Program is Jointly Funded by LLS and Janssen Research & Development, LLC WHITE PLAINS, N.Y., Oct. 28, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society has initiated a program to fund research projects seeking to better understand and, ultimately, stop progression of certain types of blood cancers from early-stage malignancies to much more lethal states of disease. The types of early-stage blood cancers the program will focus on are the "myeloid" diseases, such...

2014-10-23 08:34:28

Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility...

2014-10-21 12:32:21

WHITE PLAINS, N.Y., Oct. 21, 2014 /PRNewswire-USNewswire/ -- For the second year, The Leukemia & Lymphoma Society (LLS) will award funding to leading scientists and researchers who show promise in developing new drug therapies through the Screen to Lead Program. The collaborative program aims to support academic laboratories pursuing research directed towards medicinal chemistry and/or drug target screening in blood cancers. Members of a peer review panel select projects for...

2014-10-20 16:27:17

WHITE PLAINS, N.Y., Oct. 20, 2014 /PRNewswire-USNewswire/ -- Six academic investigators will receive grants from The Leukemia & Lymphoma Society (LLS) to support innovative ideas that that have the potential to take research in a new direction and fundamentally impact the future of blood cancer diagnosis and treatment. The second-year grant program, called The New Idea Award, looks to identify novel research strategies that involve the exploration of untested but potentially...

2014-10-20 08:31:48

Filing completed just three months after receipt of third FDA approval SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on data from a Phase 2 study evaluating the use of IMBRUVICA(®) (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM), which was led by Dr. Steven Treon from the Dana-Farber Cancer...

2014-10-15 16:30:22

University of Pennsylvania and Children's Hospital of Philadelphia Research Team Funded by LLS for More Than 22 Years Report Today in New England Journal of Medicine that 90 Percent of Patients Achieved Complete Remission WHITE PLAINS, N.Y., Oct. 15, 2014 /PRNewswire-USNewswire/ -- Funding from The Leukemia & Lymphoma Society (LLS) over the past 22 years helped advance a study published today in the New England Journal of Medicine showing that 90 percent of children and adults...

2014-10-15 04:22:13

EAST ANGUS, Quebec, October 15, 2014 /PRNewswire/ -- facebook.com/trouvonsundonneur [http://www.facebook.com/trouvonsundonneur ] facebook.com/UKyoucansaveMarcAndreSkelling [http://www.facebook.com/UKyoucansaveMarcAndreSkelling ] Marc-Andre Skelling, a 23-year-old young man needs a stem cell donor in order to save his life. Marc-Andre has been diagnosed with Hodgkin disease, a type of lymphoma, which is a cancer originating from white blood cells called...

2014-10-14 12:30:31

NEW BRUNSWICK, N.J., Oct. 14, 2014 /PRNewswire-USNewswire/ -- Actinobac Biomed Inc., has received a $905,040 Small Business Technology Transfer Grant (STTR) Phase II Award from the National Institutes of Health/ National Cancer Institute to continue to develop its drug candidate, Leukothera®, as a potential treatment for B-cell lymphomas. "This NIH grant supports our assertion that Actinobac scientists are working on breakthrough research that can make a tremendous difference for...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related